A new international study led by the Gray Faculty of Medical & Health Sciences at Tel Aviv University finds: melanoma cancer ...

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by using the patient's own T-cells to target tumors.

A panelist discusses how CD4 counts serve as measures of immune system status that typically increase by about 200 in the first year of antiretroviral therapy. Although there can be laboratory ...

Dr. Mark Davis, discoverer of the first T-cell receptor genes and Stanford Professor, to advise the Company on immunological strategies for its novel cancer treatment platformLehi Utah, Jan. 07, 2026 ...

Professors Yao Yongming and Du Xiaohui, leading a research group at the Chinese PLA General Hospital, have published groundbreaking findings demonstrating that CD4+ T lymphocytes undergo PANoptosis ...

Researchers released a consensus statement with recommendations to update T cell nomenclature and improve communication ...

It develops from the abnormal multiplication of T cells, or T-lymphocytes, a type of white blood cell essential for immune system function. The specific treatment course and prognosis for T-cell ...

Gold nanoparticles that cluster in response to T cell enzymes can predict cancer immunotherapy success days before tumors ...

B-PLL is a rare subtype that’s more aggressive than other blood cancers and has a low survival rate. However, ongoing research and clinical trials may offer new treatment options to improve outcomes.